A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
Saved in:
| Title: | A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. |
|---|---|
| Authors: | Zhang P; Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA., Narayanan E; Moderna Inc., Cambridge, MA, USA., Liu Q; Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA., Tsybovsky Y; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Boswell K; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA., Ding S; Université de Montreal, Montreal, Quebec, Canada., Hu Z; Biostatistics Research Branch, NIAID, NIH, Bethesda, MD, USA., Follmann D; Biostatistics Research Branch, NIAID, NIH, Bethesda, MD, USA., Lin Y; Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA., Miao H; Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA., Schmeisser H; Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA., Rogers D; Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA., Falcone S; Moderna Inc., Cambridge, MA, USA., Elbashir SM; Moderna Inc., Cambridge, MA, USA., Presnyak V; Moderna Inc., Cambridge, MA, USA., Bahl K; Moderna Inc., Cambridge, MA, USA., Prabhakaran M; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA., Chen X; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA., Sarfo EK; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA., Ambrozak DR; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA., Gautam R; Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, MD, USA., Martin MA; Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, MD, USA., Swerczek J; Experimental Primate Virology Section, NIAID, Poolesville, MD, USA., Herbert R; Experimental Primate Virology Section, NIAID, Poolesville, MD, USA., Weiss D; Bioqual Inc., Rockville, MD, USA., Misamore J; Bioqual Inc., Rockville, MD, USA., Ciaramella G; Moderna Inc., Cambridge, MA, USA., Himansu S; Moderna Inc., Cambridge, MA, USA., Stewart-Jones G; Moderna Inc., Cambridge, MA, USA., McDermott A; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA., Koup RA; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA., Mascola JR; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA., Finzi A; Université de Montreal, Montreal, Quebec, Canada., Carfi A; Moderna Inc., Cambridge, MA, USA., Fauci AS; Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA., Lusso P; Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA. plusso@niaid.nih.gov. |
| Source: | Nature medicine [Nat Med] 2021 Dec; Vol. 27 (12), pp. 2234-2245. Date of Electronic Publication: 2021 Dec 09. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
